ヒストン脱酸化酵素3は,流動障害に対する反応として,内皮の生存と動脈硬化症の発達において重要な役割を果たします
Anna Zampetaki1, Lingfang Zeng, Andriana Margariti
1Cardiovascular Division, King's College London BHF Centre, London, UK.
Circulation
|December 23, 2009
まとめ
ヒストン脱酸化酵素3 (HDAC3) は,内皮細胞の生存と完全性,特に血流障害の条件下において極めて重要です. その欠如は重度の動脈硬化や血管破裂につながり,その保護的役割を強調します.
科学分野:
- 心血管生物学 心血管生物学
- 分子生物学は分子生物学である.
- 動脈硬化症の研究研究
背景:
- 成熟した内皮細胞におけるヒストン脱酸化酵素3 (HDAC3) の機能は十分に理解されていません.
- HDAC3は,内皮原始細胞の分化に不可欠であることが知られている.
- この研究では,動脈硬化に弱い血流障害の領域における内皮の整合性を維持するHDAC3の役割を調査しています.
研究 の 目的:
- 成熟した内皮細胞におけるHDAC3の機能を明らかにする.
- 血流が乱れた状態で内皮の整合性を保全するHDAC3の役割を決定する.
- HDAC3が内皮細胞生存と動脈硬化症の発達に影響を与えるメカニズムを調査する.
主な方法:
- アポリポプロテインEノックアウトマウスの動脈硬化症のモデル.
- 顔の染色と大動脈の異体移植の実験を行いました.
- インビトロ内皮細胞培養は,流動の障害にさらされた.
- レンチウイルスベクトル (shHDAC3) を使用したHDAC3ノックダウン.
- タンパク質の相互作用と改変を研究するための共免疫プレシピテーションとウエスタン・ブロット分析.
主要な成果:
- HDAC3の発現は,流動が乱れた領域において,in vivoおよびin vitroで上位に調節される.
- 乱流は,Aktの相互作用によって,HDAC3の転写後の改変と安定化を誘導する.
- HDAC3のノックダウンは,内皮細胞生存率の低下,アポトーシスの増加,重度の動脈硬化病変の形成につながる.
- shHDAC3で処理された大動脈アイソグラフトは,基礎膜の破壊と血管破裂を示し,一部の移植は急速に失敗しました.
結論:
- HDAC3は,内皮細胞の生存に不可欠な分子として機能します.
- HDAC3は,Aktの活性化により,内皮の完全性を維持する.
- アポリポプロテインEノックアウトマウスにおけるHDAC3機能の喪失は,重度の動脈硬化と血管破裂を引き起こす.
関連する概念動画
Histone Modification
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Spreading of Chromatin Modifications
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Writers
The writer is an enzyme that can...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


